Navigation Links
Stereotaxis Epoch™ Solution's Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
Date:5/7/2012

ST. LOUIS, May 7, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:   STXS) will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch™ platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012. 

The formal HRS academic program features multiple invited presentations, podium presentations, and posters detailing Stereotaxis' clinical results in a wide variety of arrhythmias. A total of 11 invited podium presentations feature use of Stereotaxis magnetic navigation technology.   In addition, 13 submitted abstracts that feature or discuss Stereotaxis technology are included in this year's HRS program.  Highlights of these submitted abstracts include comparative data on VT ablation, multi-center VT data, lesion formation, pediatric outcome data, and the first large series of Vdrive™ system's clinical outcomes data.

Stereotaxis will be at booth number 1307, providing demonstrations of commercially available products and a technical suite for obtaining input on new product innovations from select physician customers.  In addition, the Company will feature at the booth a speaker series where customers will share their experiences with the Epoch™ and Odyssey™ product platforms.  In-booth speakers include:

  • Dr. Robert Schweikert from Akron General Medical Center on the Odyssey™ Solution (May 10 at 9:30 am ET);
  • Dr. Yaariv Khaykin from Southlake Regional Health Center on the Odyssey™ Solution (May 10 at 10:00 am ET); and
  • Dr. J. Peter Weiss from Intermountain Medical Center on the Epoch™ Solution (May 10 at 3:45 pm ET and May 11 at 10:00 am ET). 

Stereotaxis will unveil a broad number of product innovations for the Niobe® ES, Vdrive™ and Odyssey™ platforms scheduled to be shipped in 2012.  The innovations include advancements in linear line formation and testing, Vdrive™ offering and Odyssey™ remote collaboration. 

"Stereotaxis will launch exciting advancements at the upcoming HRS congress, which will further enhance the value we bring to the EP market," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  The 2012 innovations for the Niobe® ES and Odyssey™ product platforms as well as the new Vdrive™ platform demonstrate our continued commitment to providing new solutions for the EP market."

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.  

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis to Report First Quarter 2012 Financial Results on May 8, 2012
2. Stereotaxis Reports 2011 Financial Results; Provides 2012 Milestones
3. Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012
4. Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers
5. Stereotaxis to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Stereotaxis Reports Third Quarter Financial Results
7. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
8. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
9. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
10. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
11. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... , April 29, 2016 ... life science laboratory due to the growing demands for ... advance technology, contemporary automated systems are already adept of ... by slow, tedious and manual labor. Instrumentation continues to ... not even conceivable just a few years ago. Originally ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... – a web application that helps people assess their risk of developing Alzheimer’s ... app will provide users a “Risk Reduction Score™” that summarizes how their lifestyle ...
(Date:5/3/2016)... Baltimore, Md. (PRWEB) , ... May 03, 2016 , ... ... devastating consequences of inappropriate or excessive levels of alcohol use. Alcohol and its ... fetal alcohol spectrum disorders to the susceptibility to strokes in those 65 years and ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution of ... a random library of sequences depending on their attraction for a target molecule. ... selection is commonly performed using filters, panning, or affinity chromatography separations. However, these ...
(Date:5/3/2016)... Chicago (PRWEB) , ... May 03, 2016 , ... ... has hired award-winning creative director Joe Ferrazano to serve in the newly created ... Ferrazano will be overseeing the agency’s creative efforts in the Chicago and LA ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Elizabeth Murray ... pet parrots to join her with one on her shoulder and one on her ... a parking lot because of years of mitral valve prolapse. , The valves of ...
Breaking Medicine News(10 mins):